KDIGO/AST BK Polyomavirus Screening Protocol
BK Virus Assessment
copies/mL
Plasma BKPyV PCR
BK Virus Risk
Enter BK viral load and clinical context for risk stratification.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Routine BK polyomavirus (BKPyV) screening in kidney transplant recipients
Interpretation of plasma BK viral load results
Risk stratification for BK polyomavirus-associated nephropathy (BKPyVAN)
Guidance for immunosuppression reduction when BK viremia is detected
Monitoring response after BK-directed intervention
Screening Protocol (KDIGO/AST)
All kidney transplant recipients should be screened for BKPyV with plasma PCR every month for the first 6 months, then every 3 months until the end of the second year. BK viruria may precede viremia by weeks. Plasma BK viral load > 1000 copies/mL triggers increased monitoring; > 10,000 copies/mL warrants intervention.
How it Works
BKPyV-Associated Nephropathy
BK polyomavirus is a ubiquitous virus that establishes latency in the urinary tract. In the setting of immunosuppression, viral reactivation occurs in 30-50% of kidney transplant recipients. Approximately 10-15% develop significant viremia (> 1000 copies/mL), and 1-10% progress to BKPyVAN — a direct viral cytopathic effect on tubular epithelial cells that can lead to irreversible graft injury and loss.
Risk Stratification by Viral Load
01
< 1000 copies/mL: Low risk. Continue routine screening per protocol.
02
1000–10,000 copies/mL: Moderate risk (low-level viremia). Monitor closely. Consider reducing immunosuppression if rising.
03
10,000–100,000 copies/mL: High risk (significant viremia). Reduce immunosuppression. Consider allograft biopsy.
04
> 100,000 copies/mL: Very high risk (presumptive BKPyVAN). Immediate immunosuppression reduction. Strongly consider biopsy.
Clinical Pearls
Management Strategies
First-line intervention: Reduce CNI by 25-50% AND/OR reduce antimetabolite (MMF/MPA) by 50%
Monitor viral load every 2 weeks after reduction
If viral load continues to rise despite reduction, consider switching CNI (tacrolimus → cyclosporine)
If viral load persists > 10,000 despite maximal reduction, consider leflunomide, cidofovir, or IVIg (limited evidence)
Biopsy is essential to confirm BKPyVAN before committing to aggressive immunosuppression reduction
Rejection can occur after immunosuppression reduction — monitor renal function and consider surveillance biopsy
Next Steps
Protocol for BK Viremia
01
BK load > 1000: Increase frequency of monitoring (every 2 weeks)
02
BK load > 10,000: Reduce immunosuppression. Recheck in 2 weeks.
03
BK load > 100,000: Urgent IS reduction. Consider allograft biopsy. Recheck in 1-2 weeks.
04
If viral load decreases after IS reduction: Continue reduced IS. Monitor monthly until negative.
05
If viral load persists or rises: Consider biopsy if not already done. Consider adjunctive therapies.
The Evidence
KDIGO Guidelines
KDIGO clinical practice guideline for the care of kidney transplant recipients.
KDIGO Transplant Work Group. • Am J Transplant.. 2009;9(Suppl 3):S1–S155. BKPyV screening recommendations.
AST Guidelines
BK polyomavirus in solid organ transplantation.
Hirsch HH et al. • Am J Transplant.. 2013;13(Suppl 4):179–188. Comprehensive review of BKPyV diagnosis and management.
Origins & History
Discovery
BK polyomavirus was first isolated in 1971 from the urine of a Sudanese kidney transplant recipient (initials B.K.) at St. Mary's Hospital, London. Its role as a significant cause of post-transplant nephropathy was not fully appreciated until the late 1990s-2000s, when improved immunosuppression led to a dramatic increase in BKPyVAN incidence. Routine screening protocols were widely adopted following the 2009 KDIGO guidelines.
Last Comprehensive Review: 2026-07-17